循环可溶性Fms样酪氨酸激酶在非子痫前期肾脏疾病中的作用
本文综述了可溶性Fms样酪氨酸激酶(sFlt-1/sVEGFR1)在非子痫前期肾脏疾病中的临床与实验研究。sFlt-1是VEGF天然拮抗剂,循环sFlt-1在CKD和肾移植后等肾功能受损疾病中升高,与内皮功能障碍、肾功能损害、心血管疾病和全因死亡等不良结局相关,但对动脉粥样硬化和糖尿病肾病加重有保护作用。
要点
- 循环sFlt-1在CKD和肾移植后患者中升高,与不良结局相关。
- sFlt-1对肾功能障碍相关的动脉粥样硬化和糖尿病肾病加重有保护作用。
- sFlt-1在非子痫前期肾脏疾病中的临床应用价值尚待明确。
核心结论
- 循环sFlt-1在多种非子痫前期肾脏疾病中升高,与不良结局相关,但也可发挥保护作用。
研究设计与样本
- 本文为叙述性综述,汇总关于sFlt-1在非子痫前期肾脏疾病中的临床和实验研究。
主要发现
- 在CKD和肾移植后患者中观察到循环sFlt-1与内皮功能障碍、肾功能损害、心血管疾病和全因死亡等严重结局相关。
- sFlt-1对肾功能障碍相关的动脉粥样硬化和糖尿病肾病加重具有保护作用。
临床怎么用
- sFlt-1可能作为非子痫前期肾脏疾病中评估内皮功能障碍和心血管风险的生物标志物,但需进一步研究。
局限性
- 本文为综述,未提供原始数据,sFlt-1的临床效用仍需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Soluble Fms-like tyrosine kinase (sFlt-1/sVEGFR1) is a naturally occurring antagonist of vascular endothelial growth factor (VEGF). Despite being a secreted, soluble protein lacking cytoplasmic and transmembrane domains, sFlt-1 can act locally and be protective against excessive microenvironmental VEGF concentration or exert autocrine functions independently of VEGF. Circulating sFlt-1 may indiscriminately affect endothelial function and the microvasculature of distant target organs. The clinical significance of excess sFlt-1 in kidney disease was first shown in preeclampsia, a major renal complication of pregnancy. However, circulating sFlt-1 levels appear to be increased in various diseases with varying degrees of renal impairment. Relevant clinical associations between circulating sFlt-1 and severe outcomes (e.g., endothelial dysfunction, renal impairment, cardiovascular disease, and all-cause mortality) have been observed in patients with CKD and after kidney transplantation. However, sFlt-1 appears to be protective against renal dysfunction-associated aggravation of atherosclerosis and diabetic nephropathy. Therefore, in this study, we provide an update on sFlt-1 in several kidney diseases other than preeclampsia, discuss clinical findings and experimental studies, and briefly consider its use in clinical practice.
引用
- Wewers TM, Schulz A, Nolte I, et al. Circulating Soluble Fms-like Tyrosine Kinase in Renal Diseases Other than Preeclampsia. J Am Soc Nephrol. 2021. PMID: 34155060. doi:10.1681/ASN.2020111579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。